Table 2.
Prevention Medication Persistence by Drug Class
| Drug Class | Prescription at Discharge, No. (%) (N=270) | Continued Use at Follow‐Up, No. (%) | Persistencea, No. (%) |
|---|---|---|---|
| Antihypertensive | 212 (78.5) | 185 (87.3) | 82 (38.7) |
| Diuretic | 82 (30.4) | 20 (24.4) | |
| β‐Blocker | 112 (41.5) | 41 (36.6) | |
| CCB | 67 (24.8) | 32 (47.8) | |
| ACE inhibitor | 110 (40.7) | 76 (69.1) | |
| ARB | 40 (14.8) | 19 (47.5) | |
| Other | 16 (5.9) | 6 (37.5) | |
| Antilipidemic | 197 (73.0) | 160 (81.2) | 126 (64.0) |
| Statin | 192 (71.1) | 151 (78.7) | |
| Nonstatin | 45 (16.7) | 13 (28.9) | |
| Antithrombotic | 187 (69.3) | 166 (88.8) | 149 (79.7) |
| Antiplatelet | 164 (60.7) | 143 (87.2) | |
| Anticoagulant | 47 (17.4) | 28 (59.6) | |
| Combination use | |||
| Antihypertensive and antilipidemic | 167 (61.9) | 121 (72.46) | 44 (26.4) |
| Antihypertensive and antithrombotic | 158 (58.5) | 122 (77.2) | 51 (32.3) |
| Antihypertensive, antilipidemic, and antithrombotic | 134 (49.6) | 94 (70.2) | 37 (27.6) |
Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. aPersistence at time of follow‐up was defined as continuation on all or at least two medications based on drug class prescribed at hospital discharge.